XT4 Stock Overview
Develops diagnostic method to investigate the spread of rectal cancer to nearby lymph nodes.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
NanoEcho AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.016 |
52 Week High | SEK 0.026 |
52 Week Low | SEK 0.013 |
Beta | 0 |
11 Month Change | -34.14% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -33.33% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
XT4 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | -12.8% | -0.6% | 1.0% |
1Y | n/a | 10.5% | 19.0% |
Return vs Industry: Insufficient data to determine how XT4 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how XT4 performed against the German Market.
Price Volatility
XT4 volatility | |
---|---|
XT4 Average Weekly Movement | 37.3% |
Medical Equipment Industry Average Movement | 5.1% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XT4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine XT4's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | n/a | Linda Persson | nanoecho.se |
NanoEcho AB (publ) develops diagnostic method to investigate the spread of rectal cancer to nearby lymph nodes. The company was incorporated in 2013 and is based in Lund, Sweden.
NanoEcho AB (publ) Fundamentals Summary
XT4 fundamental statistics | |
---|---|
Market cap | €3.94m |
Earnings (TTM) | €0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs XT4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XT4 income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €0 |
Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
Oct 24, 2024
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did XT4 perform over the long term?
See historical performance and comparison